Pulmonary Adenocarcinoma Approaches to Treatment 1st edition by Leora Horn 0323554342 9780323554343

Pulmonary Adenocarcinoma: Approaches to Treatment 1st edition by Leora Horn – Ebook PDF Instant Download/DeliveryISBN:   0323554342 9780323554343 

Full download Pulmonary Adenocarcinoma: Approaches to Treatment 1st edition after payment.

Product details:

ISBN-10 :  0323554342 

ISBN-13 : 9780323554343

Author :  Leora Horn 

Get a quick, expert overview of the latest treatment and management approaches for adenocarcinoma of the lung, including novel therapeutics in immunotherapy and targeted therapies. This practical title, edited by Dr. Leora Horn, offers succinct coverage of clinically-focused topics and guidelines, making it an ideal resource for practicing and trainee oncologists and other members of the cancer care team.

Pulmonary Adenocarcinoma: Approaches to Treatment 1st Table of contents:

Chapter 1. The Surgical Management of Pulmonary Adenocarcinoma
Introduction
Staging
Assessing Surgical Candidacy
Surgical Management of Lung Cancer
Surgical Approach to Lung Cancer
Important Surgical Considerations
Conclusion
Chapter 2. Pulmonary Adenocarcinoma—Pathology and Molecular Testing
Introduction
Histological Classification
Clinical Relevance of Adenocarcinoma Subtype Classification
Pathological Staging of Lung Adenocarcinoma—UICC/AJCC Eighth Edition
Molecular Classification
Transcriptomic Classifications
Oncogenic Driver Mutations and Molecular Testing in Lung Adenocarcinoma
Epidermal Growth Factor Receptor
Anaplastic Lymphoma Kinase
ALK and ROS1 Testing
Others Driver Oncogenes
Liquid Biopsies
Program Death Ligand 1
Conclusions
Chapter 3. Adjuvant and Neoadjuvant Therapy in Non–Small-Cell Lung Cancer
Introduction
Adjuvant Chemotherapy
Stage I Disease
Choice of Chemotherapy
Adjuvant Radiation Therapy
Neoadjuvant Chemotherapy
Molecularly Targeted Therapy
Immunotherapy
Neoadjuvant Immunotherapy
Conclusions and Future Directions
Chapter 4. Management of Locally Advanced Lung Cancer
Introduction
Anatomy
Screening
Manifestations
Workup
Histology
Staging (Eighth Edition) (Tables 4.3 and 4.4)
Management
Resectable LA-NSCLC
Superior Sulcus Tumors
Unresectable LA-NSCLC
Targeted Therapies
Immunotherapy
Radiotherapy
Volumes
Modalities
Chapter 5. First-Line Therapy for Wild-Type Patients
Chemotherapy
Duration of Chemotherapy
Bevacizumab
Maintenance Therapy
Immunotherapy
Elderly Patients
Impaired Performance Status
Conclusions
Chapter 6. Lung Adenocarcinoma: Second-Line Treatment
Introduction
Cytotoxic Chemotherapy–Monotherapy
Combination Chemotherapy
Targeted Agents
Immunotherapy
Conclusion
Chapter 7. Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Epidemiology
Diagnosis
Treatment
Acquired Resistance to First- and Second-Generation TKIs and the Development of Third-Generation EGFR TKIs
Cytotoxic Chemotherapy
Immune Therapy
Adjuvant Therapy
Treatment Beyond Progression and Oligoprogressive Disease
CNS Metastases
Small-Cell Lung Cancer Transformation
Exon 20 Insertion Mutations
Treatment of Selected TKI Toxicities
Summary of Current Treatment Recommendations
Future Directions
Chapter 8. Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non–Small Cell Lung Cancer (NSCLC)
Introduction
Clinical Features of Anaplastic Lymphoma Kinase Positive Non–Small Cell Lung Cancer
Testing for Anaplastic Lymphoma Kinase
Approach to Advanced-Stage Anaplastic Lymphoma Kinase Patient
Crizotinib
Next-Generation ALK Inhibitors in Crizotinib-Treated Patients
Next-Generation ALK TKIs as Front-Line Therapy
Alectinib
AF-001JP
JALEX (Table 8.3)
ALEX (Table 8.3)
Summary of ALEX and JALEX
Ceritinib
Other Drugs
Resistance to Next-Generation ALK Inhibitors
Sequence of ALK Inhibitors (Figs. 8.1 and 8.2)
Non-ALK-Directed Therapy
Central Nervous System Metastases
Management of Patients With Oligometastatic Disease
Early-Stage and Locally Advanced ALK Positive NSCLC
Future Directions
Chapter 9. Targeted Therapy in Non–Small-Cell Lung Cancer (Beyond Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase)
Introduction
ROS1
BRAF
Mesenchymal–Epithelial Transition
RET
Human Epidermal Growth Factor Receptor 2
Neurotrophin Tyrosine Receptor Kinase–Mutated NSCLC
Conclusions
Chapter 10. Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors
Introduction
Previously Treated Advanced Non–Small Cell Lung Cancer
Treatment-Naïve Advanced Non–Small Cell Lung Cancer
Unresectable Stage III Non–Small Cell Lung Cancer
Safety and Management of Toxicity
Biomarkers
Treatment Duration
Ongoing Studies/Future Directions

People also search for Pulmonary Adenocarcinoma: Approaches to Treatment 1st:

metastatic pulmonary adenocarcinoma icd 10
    
poorly differentiated pulmonary adenocarcinoma
    
stage 4 pulmonary adenocarcinoma
    
moderately differentiated pulmonary adenocarcinoma
    
pulmonary adenocarcinoma icd 10

Tags:

Pulmonary,Adenocarcinoma,Approaches,Treatment,Leora Horn